Novel Antiangina Drug Studied in DiabetesThe novel selective serotonin 2A receptor antagonist sarpogrelate produces numerous physiologic benefits in type 2 diabetic patients with stable angina, Dr. Hideki Watanabe said at the annual scientific sessions of the American Heart Association.
The investigational agent has shown promise as an antianginal drug in preliminary clinical studies. But this was not the focus of Dr. Watanabe's 30-patient, 12-month randomized trial, designed instead to examine the mechanisms involved in sarpogrelate's antianginal effects.
In the study, sarpogrelate at 300 mg/day significantly improved vascular endothelial function, aortic stiffness, and exercise tolerance. Moreover, it also reduced insulin resistance, systemic inflammation, and markers of oxidative stress. All these benefits were maintained through the full 12 months of the study, said Dr. Watanabe of the Kunu Medical Association Hospital, Joso, Japan.
Levels of high-sensitivity C-reactive protein in the sarpogrelate group fell from 1.02 mg/dL at baseline to 0.51 mg/dL at 6 months and 0.30 mg/dL at 12 months while remaining unchanged in controls. Insulin resistance as estimated by homeostasis model assessment fell from 5.7 at baseline to 3.2 at 1 year, with no significant change in controls. Exercise tolerance as reflected in time to a 0.10-mV ST-segment depression on a Bruce treadmill protocol rose from 345 seconds at baseline to 490 seconds in the sarpogrelate group and 360 seconds in controls.
Most participants in the study, sponsored by Mitsubishi Pharma, were on a calcium channel blocker, a β-blocker, and nitroglycerin for angina control, Dr. Watanabe said.
The investigational agent has shown promise as an antianginal drug in preliminary clinical studies. But this was not the focus of Dr. Watanabe's 30-patient, 12-month randomized trial, designed instead to examine the mechanisms involved in sarpogrelate's antianginal effects.
In the study, sarpogrelate at 300 mg/day significantly improved vascular endothelial function, aortic stiffness, and exercise tolerance. Moreover, it also reduced insulin resistance, systemic inflammation, and markers of oxidative stress. All these benefits were maintained through the full 12 months of the study, said Dr. Watanabe of the Kunu Medical Association Hospital, Joso, Japan.
Levels of high-sensitivity C-reactive protein in the sarpogrelate group fell from 1.02 mg/dL at baseline to 0.51 mg/dL at 6 months and 0.30 mg/dL at 12 months while remaining unchanged in controls. Insulin resistance as estimated by homeostasis model assessment fell from 5.7 at baseline to 3.2 at 1 year, with no significant change in controls. Exercise tolerance as reflected in time to a 0.10-mV ST-segment depression on a Bruce treadmill protocol rose from 345 seconds at baseline to 490 seconds in the sarpogrelate group and 360 seconds in controls.
Most participants in the study, sponsored by Mitsubishi Pharma, were on a calcium channel blocker, a β-blocker, and nitroglycerin for angina control, Dr. Watanabe said.
No comments:
Post a Comment